Treatment of systemic sclerosis with tocilizumab

Rheumatology (United Kingdom)

Volumn 54, Issue 2, 2015, Pages 371-372

  Das Neves, Marisa Fernandes ^a,b   Oliveira, Susana ^a   Amaral, Marta C ^a,b   Alves, José Delgado ^a,b  

^a HOSPITAL FERNANDO FONSECA   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BOSENTAN; C REACTIVE PROTEIN; ETANERCEPT; HEMOGLOBIN; ILOPROST; METHOTREXATE; STEROID; TOCILIZUMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CASE REPORT; COPING BEHAVIOR; DISEASE COURSE; DRUG SUBSTITUTION; FACIAL TELANGIECTASIAS; FEMALE; FINGER ULCER; GASTROESOPHAGEAL REFLUX; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; INTESTINE INFARCTION; LUNG FUNCTION TEST; LUNG VOLUME; MALABSORPTION; MIDDLE AGED; PERSONAL EXPERIENCE; PRIORITY JOURNAL; SCORING SYSTEM; SKINFOLD; SKINFOLD THICKNESS; SYNOVITIS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TELANGIECTASIA; WEIGHT REDUCTION; CHRONIC DISEASE; SCLERODERMA, SYSTEMIC;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 84925581704     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu435     Document Type: Article

References (8)

1. Leask A. Emerging targets for the treatment of scleroderma. Expert Opin Emerg Drugs 2012;17:173-9.
2. Denton CP, Ong VH. Targeted therapies for systemic sclerosis. Nat Rev Rheumatol 2013;9:451-64.
3. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Inter J Rheumatol 2011;2011:721608.
4. Khan K, Xu S, Nihtyanova S et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012;71:1235-42.
5. O'Reilly S, Cant R, Ciechomska M, van Laar JM. Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunol 2013;2:e4.
6. Shima Y, Kuwahara Y, Murota H et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010;49:2408-12.
7. Elhai M, Meunier M, Matucci-Cerinic M et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72:1217-20.
8. Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.